No Data
No Data
AIM ImmunoTech Analyst Ratings
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Cuts Target Price to $1
AIM ImmunoTech Price Target Lowered to $1 From $2 at Maxim
Express News | AIM ImmunoTech Inc : Maxim Group Cuts Target Price to $1 From $2
12 Health Care Stocks Moving In Thursday's After-Market Session
AIM ImmunoTech Granted U.S. Patent for Ampligen for the Treatment of Endometriosis
No Data
No Data